<PAGE>

                                                   AmeriPath, Inc. Press Release
                                                                     Page 1 of 2

                                                                    Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:
Gregory A. Marsh                              Michelle D. Getty
Vice President & CFO                          Investor Relations
AmeriPath, Inc.                               AmeriPath, Inc.
561-712-6211                                  561-712-6260
                                              E-mail:  invrel@ameripath.com


                 AMERIPATH ANNOUNCES INCREASED MALPRACTICE COSTS
                   AND COMMENTS ON MEDICARE PROPOSAL FOR 2003

Riviera Beach, FL, July 1, 2002 - AmeriPath, Inc. (Nasdaq:PATH), a leading
national provider of cancer diagnostics, genomics, and related information
services, today announced that it has renewed its medical malpractice coverage
for the policy year effective July 1, 2002 to June 30, 2003. Despite an
excellent claims history, the Company encountered a severe malpractice
environment resulting in an annualized renewal rate in excess of budget by $6 to
$8 million. As a result, the Company anticipates the balance of 2002 to be
negatively impacted by $.03 to $.04 per quarter for the remaining two quarters
of 2002.

"This premium increase is a function of market conditions and not a result of
abnormal loss experience at AmeriPath," said James C. New, Chairman and CEO.
"Malpractice insurance has been a well-publicized problem in healthcare, in
fact, it is becoming financially paralyzing in many sectors. We believe some
type of government reform will be necessary before the market experiences a
return to acceptable levels."

Medicare Proposal

AmeriPath is disappointed by the Department of Health and Human Services'
proposed revisions to Medicare payment under the physician fee schedule for
calendar year 2003. These proposals are subject to comment and, in the Company's
experience, there can be differences between proposed and final fee schedules,
which are normally published in November. Also, there is existing legislation in
Congress, which will minimize the proposal's impact. AmeriPath will work with
the College of American Pathologists (CAP) to provide feedback on the proposed
rates. Should rates be implemented per the Center for Medicare and Medicaid
Services (CMS) proposed schedule, AmeriPath would experience up to a $10 million
revenue reduction. If the House Ways and Means recommendation of 2% increase in
the conversion factor is adopted, the negative revenue impact would be reduced
to $3 million. The Company believes the smaller number is the most likely. The
Company will provide `03 guidance at the end of July on its quarterly conference
call.

                                    - more -

<PAGE>

                                                   AmeriPath, Inc. Press Release
                                                                     Page 2 of 2

AmeriPath will hold a conference call on Tuesday, July 2, 2002 at 10:00 a.m.
Eastern Time. This conference call will offer an audio broadcast live on the
Internet and can be accessed at
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=PATH&script=1020&item
_id=ew,644773,1&layout=6 or at the Company's website, http://www.ameripath.com.
A playback of the call will be available from 12:00 p.m. July 2 to 12:00 p.m.
July 4. PostView dial-in number of the telephone replay is 800-633-8284, ID
#20734071.

AmeriPath is a leading national provider of cancer diagnostics, genomics, and
related information services. The Company's extensive diagnostics infrastructure
includes the Center for Advanced Diagnostics (CAD), a division of AmeriPath. CAD
provides specialized diagnostic testing and information services including
Fluorescence In-Situ Hybridization (FISH), Flow Cytometry, DNA Analysis,
Polymerase Chain Reaction (PCR), Molecular Genetics, Cytogenetics and HPV
Typing. Additionally, AmeriPath provides clinical trial and research development
support to firms involved in developing new cancer and genomic diagnostics and
therapeutics.

                                       ###

The statements contained in this press release include "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements - which are sometimes identified by words
such as "may", "should", "believe", "expect", "anticipate", "estimate" and
similar expressions and which include any financial or operating estimates,
forecasts or projections - are subject to a number of risks and uncertainties,
many of which involve factors or circumstances that are beyond the Company's
control. These risks and uncertainties could cause actual results to differ
materially from results anticipated by forward-looking statements. These risks
and uncertainties include: the extent of success of the Company's operating
initiatives and growth strategies; ability to manage growth; access to capital
on satisfactory terms; general economic conditions; terrorism or an escalation
of hostilities or war; competition and changes in competitive factors; federal
and state healthcare regulation (and compliance); reimbursement rates under
government and third party healthcare programs and the payments received under
such programs; changes in coding; changes in technology; dependence upon
pathologists and customer contracts; the ability to attract, motivate, and
retain pathologists; labor, technology and insurance costs; marketing and
promotional efforts; the availability of pathology practices in appropriate
locations that the Company is able to acquire on suitable terms or develop; and
the successful completion and integration of acquisitions (and achievement of
planned or expected synergies). The forward-looking statements in this press
release are made as of the date hereof based on management's current beliefs and
expectations, and the Company undertakes no obligation to update or revise any
such statements. Further information regarding risks, uncertainties and other
factors that could affect the Company's financial or operating results or that
could cause actual results to differ materially from those expected, estimated
or anticipated are included in the Company's annual, quarterly, and other
reports and filings with the SEC.

Editor's Note: This release is also available at http://www.ameripath.com

